$168.75 +1.28 (%) Pharmacyclics Inc - NASDAQ

Jan. 30, 2015 | 04:00 PM

Partner Headlines

  1. Stocks That Battle Cancer Were The Best-Performing Biotechs In January

    Benzinga | Jan. 30, 2015 | 13:03PM EST
  2. IBD 50 Turns In Solid Week As Market Uptrend Resumes

    IBD | Jan. 23, 2015 | 18:34PM EST
  3. 10 Biotech Stories You Might've Missed This Week

    Benzinga | Jan. 15, 2015 | 13:18PM EST
  4. Imbruvica lifts Pharmacyclics

    IBD | Jan. 13, 2015 | 18:51PM EST
  5. Mid-Day Market Update: Pharmacyclics Surges On Strong Preliminary 2014 Results; Fresh Market Shares Slip

    Benzinga | Jan. 13, 2015 | 13:24PM EST
  6. Mid-Morning Market Update: Markets Open Higher; Alcoa Profit Beats Expectations

    Benzinga | Jan. 13, 2015 | 11:30AM EST
  7. Pharmacyclics Soars As Imbruvica Sales Beat Estimates

    IBD | Jan. 13, 2015 | 11:29AM EST
  8. Benzinga's Volume Movers

    Benzinga | Jan. 13, 2015 | 10:36AM EST
  9. Morning Market Gainers

    Benzinga | Jan. 13, 2015 | 09:49AM EST
  10. Tuesday Morning Movers: ChannelAdvisor Plummets

    Benzinga | Jan. 13, 2015 | 09:29AM EST
  11. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

    Benzinga | Jan. 12, 2015 | 08:55AM EST
  12. UPDATE: BTIG Initiates Coverage On Pharmacyclics

    Benzinga | Jan. 6, 2015 | 07:38AM EST
  13. IMBRUVICA Data Demonstrates Efficacy in Previously Untreated and Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients

    Benzinga | Jan. 5, 2015 | 09:02AM EST
  14. At Pharmacyclics, Employees Train To Become Geniuses

    IBD | Jan. 2, 2015 | 16:27PM EST
  15. Toys, Department Stores Rock, But Biotechs Tumble

    IBD | Dec. 23, 2014 | 12:06PM EST
  16. Pharmacyclics Reports IMRUVICA Data Shows Safety, Durability of Response at Two-Year Follow-Up in Mantle Cell Lymphoma

    Benzinga | Dec. 9, 2014 | 09:02AM EST
  17. AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate Imbruvica In Hematologic Cancers

    Benzinga | Nov. 4, 2014 | 14:35PM EST
  18. Wainwright Sees TG Therapeutics As Take-Out Target

    Benzinga | Oct. 27, 2014 | 13:20PM EST
  19. Pharmacyclics Enters Into Agreement With Roche To Evaluate IMBRUVICA And GAZYVA In Lymphoma And Leukemia

    Benzinga | Oct. 16, 2014 | 14:47PM EST
  20. Pharmacyclics and Servier Agree To Conclude Pan-HDAC Inhibitor Collaboration

    Benzinga | Sep. 25, 2014 | 16:02PM EST
  21. Gilead's Zydelig Approved In EU; Imbruvica In Wings

    IBD | Sep. 19, 2014 | 12:17PM EST
  22. UPDATE: Morgan Stanley Reiterates On Pharmacyclics, Inc. Following VA Contract News

    Benzinga | Sep. 11, 2014 | 09:53AM EST
  23. Pharmacyclics Price Target Cut On Higher Spending

    IBD | Sep. 8, 2014 | 13:02PM EST
  24. Infinity Pharma Joins AbbVie On Blood Cancer Drug

    IBD | Sep. 3, 2014 | 13:20PM EST
  25. Celgene, Gilead Lead Big Biotech Stock Movers

    IBD | Aug. 26, 2014 | 14:38PM EST
  26. Target Expected To Be Right On Target With Earnings

    Benzinga | Aug. 20, 2014 | 07:13AM EST
  27. Pharmacyclics Appoints Chief Commercial Officer

    Benzinga | Aug. 18, 2014 | 16:05PM EST
  28. Pharmacyclics Q2 Earnings Get Mixed Reception

    IBD | Aug. 1, 2014 | 12:35PM EST
  29. Credit Suisse Raises Q2 Imbruvica Sales Forecast For Pharmacyclics

    Benzinga | Jun. 30, 2014 | 09:18AM EST
  30. Pharmacyclics

    IBD | Jun. 9, 2014 | 18:41PM EST
  31. Surges In Biotech Short Interest (INCY, PCYC, RGEN)

    Benzinga | May. 11, 2014 | 16:35PM EST
  32. AbbVie Beats Q1 Estimates, Downplays HCV 'Price War'

    IBD | Apr. 25, 2014 | 12:30PM EST
  33. Mid-Afternoon Market Update: Markets Continue to Take a Beating as Rite Aid Moves Higher

    Benzinga | Apr. 10, 2014 | 15:34PM EST
  34. Mid-Day Market Update: Rite Aid Shares Gain On Upbeat Earnings; Imperva Drops

    Benzinga | Apr. 10, 2014 | 12:48PM EST
  35. Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data

    Benzinga | Apr. 8, 2014 | 08:01AM EST
  36. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga | Mar. 27, 2014 | 15:57PM EST
  37. Morgan Stanley Starts Pharmacyclics With Equal-Weight; $120 PT -Reuters

    Benzinga | Mar. 26, 2014 | 16:27PM EST
  38. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, MDVN, PCYC)

    Benzinga | Mar. 26, 2014 | 07:56AM EST
  39. Pharmacyclics target raised

    IBD | Mar. 20, 2014 | 18:47PM EST
  40. Pharmacyclics Drug Imbruvica Beats Rivals: Nomura

    IBD | Mar. 20, 2014 | 11:25AM EST
  41. Kiplinger's Tom Petruno Breaks Down The Best Bull Market Stocks

    Benzinga | Mar. 19, 2014 | 13:31PM EST
  42. WuXi Pharma Q4 Earnings Top, But Q1 Guidance Misses

    IBD | Mar. 5, 2014 | 17:38PM EST
  43. Weekly Insider Sells Highlight: BX, PCYC, MAS, ITMN

    GuruFocus | Mar. 3, 2014 | 09:31AM EST
  44. Pharmacyclics Hits High As Imbruvica Launches Big

    IBD | Feb. 21, 2014 | 12:31PM EST
  45. FDA Approvals And Changes For The Week Ending February 14, 2014

    Benzinga | Feb. 18, 2014 | 16:17PM EST
  46. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga | Feb. 13, 2014 | 10:18AM EST
  47. Pharmacyclics up on FDA OK

    IBD | Feb. 12, 2014 | 18:43PM EST
  48. Pharmacyclics' Imbruvica Wins Second Cancer Approval

    IBD | Feb. 12, 2014 | 14:05PM EST
  49. Pharmacyclics: Facts Behind $10B Market Cap

    YCharts | Jan. 22, 2014 | 09:25AM EST
  50. $10B Market By 2022: Pharmacyclic’s Piece Of It

    YCharts | Jan. 21, 2014 | 13:29PM EST
Trading Center